Buscar por Autor Drulak, M.

Ir a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
O introducir las primeras letras:  
Mostrando resultados 1 a 4 de 4
Fecha de publicaciónTítuloAutor(es)
2011Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsGathe, J.; Andrade-Villanueva, J.; Santiago, S.; Horban, A.; Nelson, M.; Cahn, P.; Bogner, J.; Spencer, D.; Podzamczer, D.; Yong, C.-L.; Nguyen, T.; Zhang, W.; Drulak, M.; Quinson, A.-M.; Gathe, J., Therapeutic Concepts, Houston, TX, United States; Andrade-Villanueva, J., Hospital Civil de Guadalajara, CUCS, U de G, Guadalajara, Mexico; Santiago, S., Care Resource, Miami, FL, United States; Horban, A., Warsaw Medical University, Hospital for Infectious Diseases, Warsaw, Poland; Nelson, M., Chelsea and Westminster Hospital, London, United Kingdom; Cahn, P., Fundacion Huesped, Buenos Aires, Argentina; Bogner, J., University Hospital of Munich, Downtown Campus, Munich, Germany; Spencer, D., Edenvale, Guateng, South Africa; Podzamczer, D., Hosp. de Bellvitge l'Hospitalet de Llobregat, Barcelona, Spain; Yong, C.-L., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Nguyen, T., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Zhang, W., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Drulak, M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Quinson, A.-M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States
2011Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsGathe, J.; Andrade-Villanueva, J.; Santiago, S.; Horban, A.; Nelson, M.; Cahn, P.; Bogner, J.; Spencer, D.; Podzamczer, D.; Yong, C.-L.; Nguyen, T.; Zhang, W.; Drulak, M.; Quinson, A.-M.; Gathe, J., Therapeutic Concepts, Houston, TX, United States; Andrade-Villanueva, J., Hospital Civil de Guadalajara, CUCS, U de G, Guadalajara, Mexico; Santiago, S., Care Resource, Miami, FL, United States; Horban, A., Warsaw Medical University, Hospital for Infectious Diseases, Warsaw, Poland; Nelson, M., Chelsea and Westminster Hospital, London, United Kingdom; Cahn, P., Fundacion Huesped, Buenos Aires, Argentina; Bogner, J., University Hospital of Munich, Downtown Campus, Munich, Germany; Spencer, D., Edenvale, Guateng, South Africa; Podzamczer, D., Hosp. de Bellvitge l'Hospitalet de Llobregat, Barcelona, Spain; Yong, C.-L., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Nguyen, T., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Zhang, W., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Drulak, M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Quinson, A.-M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States
2013Verxve 144-week results: Nevirapine extended release (nvp xr) qd versus nvp immediate release (ir) bid with ftc/tdf in treatment-naive hiv-1 patientsBrinson, C.; Bogner, J.R.; Nelson, M.; Podzamczer, D.; Quinson, A.M.; Drulak, M.; Andrade-Villanueva, J.; Cahn, P.; Santiago, S.; Gathe, J.; Brinson, C., Central Texas Clinical Research, Austin, TX, United States; Bogner, J.R., University Hospital of Munich, Munich, Germany; Nelson, M., St Stephen's AIDS Trust, London, United Kingdom; Podzamczer, D., Hospital Universitari de Bellvitge, Barcelona, Spain; Quinson, A.M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Drulak, M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Andrade-Villanueva, J., Universidad de Guadalajara, Guadalajara, Mexico; Cahn, P., Fundaci�n Husp�d, Buenos Aires, Argentina; Santiago, S., Care Resource, Miami, FL, United States; Gathe, J., Therapeutic Concepts, Houston, TX, United States
2013Verxve 144-week results: Nevirapine extended release (nvp xr) qd versus nvp immediate release (ir) bid with ftc/tdf in treatment-naive hiv-1 patientsBrinson, C.; Bogner, J.R.; Nelson, M.; Podzamczer, D.; Quinson, A.M.; Drulak, M.; Andrade-Villanueva, J.; Cahn, P.; Santiago, S.; Gathe, J.; Brinson, C., Central Texas Clinical Research, Austin, TX, United States; Bogner, J.R., University Hospital of Munich, Munich, Germany; Nelson, M., St Stephen's AIDS Trust, London, United Kingdom; Podzamczer, D., Hospital Universitari de Bellvitge, Barcelona, Spain; Quinson, A.M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Drulak, M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Andrade-Villanueva, J., Universidad de Guadalajara, Guadalajara, Mexico; Cahn, P., Fundación Huspéd, Buenos Aires, Argentina; Santiago, S., Care Resource, Miami, FL, United States; Gathe, J., Therapeutic Concepts, Houston, TX, United States